The primary aim of this study was to assess hepatic risk—specifically MASLD—in patients with IBD by identifying risk factors, exploring links between these digestive disorders, and analyzing correlations between IBD characteristics (Harvey–Bradshaw Index (HBI), Total Mayo Score, C-reactive protein (CRP), fecal calprotectin) and MASLD features (steatosis and fibrosis severity). This evidence concerns the gene CRP and inflammatory bowel disease.